Iovance Biotherapeutics (IOVA) Stock Price, News & Analysis

Company Overview

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Key Stats

• Today's Range: $3.98 to $3.98
• 50-Day Range: $5.26 to $7.79
• 52-Week Range: $3.98 to $18.24
• Volume: 2.36 million shs
• Average Volume: 8.45 million shs
• Market Capitalization: $1.15 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.90
• Consensus Rating: Moderate Buy

Iovance Biotherapeutics Stock Analysis - MarketRank™

Iovance Biotherapeutics scored higher than 84% of companies evaluated by MarketBeat, and ranked 177th out of 956 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Iovance Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Iovance Biotherapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Iovance Biotherapeutics are expected to grow in the coming year, from ($1.24) to ($0.88) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Iovance Biotherapeutics is -3.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Iovance Biotherapeutics is -3.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Iovance Biotherapeutics has a P/B Ratio of 2.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

25.74% of the float of Iovance Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Iovance Biotherapeutics has a short interest ratio ("days to cover") of 8.6.

Change versus previous month

Short interest in Iovance Biotherapeutics has recently decreased by 0.49%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Iovance Biotherapeutics does not currently pay a dividend.

Dividend Growth

Iovance Biotherapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -1.09

Percentage of Shares Shorted

25.74% of the float of Iovance Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Iovance Biotherapeutics has a short interest ratio ("days to cover") of 8.6.

Change versus previous month

Short interest in Iovance Biotherapeutics has recently decreased by 0.49%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.74

News Sentiment

Iovance Biotherapeutics has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 19 news articles for Iovance Biotherapeutics this week, compared to 6 articles on an average week.

Search Interest

89 people have searched for IOVA on MarketBeat in the last 30 days. This is an increase of 68% compared to the previous 30 days.

MarketBeat Follows

Only 26 people have added Iovance Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -26% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Iovance Biotherapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.10% of the stock of Iovance Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

77.03% of the stock of Iovance Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IOVA Stock Analysis - Frequently Asked Questions

How have IOVA shares performed this year?

Iovance Biotherapeutics' stock was trading at $7.40 at the start of the year. Since then, IOVA stock has decreased by 28.9% and is now trading at $5.26.
View the best growth stocks for 2025 here.

How were Iovance Biotherapeutics' earnings last quarter?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) announced its earnings results on Thursday, February, 27th. The biotechnology company reported ($0.26) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.26). Iovance Biotherapeutics had a negative trailing twelve-month return on equity of 58.43% and a negative net margin of 451.25%.

Who are Iovance Biotherapeutics' major shareholders?

Top institutional investors of Iovance Biotherapeutics include Vanguard Group Inc. (9.03%), Hood River Capital Management LLC (2.95%), Soleus Capital Management L.P. (2.15%) and Geode Capital Management LLC (1.93%). Insiders that own company stock include Wayne P Rothbaum, Merrill A Mcpeak, Iain D Dukes, Ryan D Maynard and Frederick G Vogt.
View institutional ownership trends.

How do I buy shares of Iovance Biotherapeutics?

Shares of IOVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Iovance Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Iovance Biotherapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), CrowdStrike (CRWD) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 2/27/2025
• Today: 2/28/2025
• Next Earnings (Estimated): 5/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IOVA
• CIK: 1425205
• Web: www.iovance.com
• Phone: (650) 260-7120
• Fax: N/A
• Employees: 500
• Year Founded: 2013

Price Target and Rating

• Average Stock Price Target: $20.90
• High Stock Price Target: $32.00
• Low Stock Price Target: $7.50
• Potential Upside/Downside: +297.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.49)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-444,040,000.00
• Net Margins: -451.25%
• Pretax Margin: -458.01%
• Return on Equity: -58.43%
• Return on Assets: -45.48%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.22
• Quick Ratio: 3.90

Sales & Book Value

• Annual Sales: $90.86 million
• Price / Sales: 17.64
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.28 per share
• Price / Book: 2.31

Miscellaneous

• Outstanding Shares: 304,781,000
• Free Float: 267,902,000
• Market Cap: $1.60 billion
• Optionable: Optionable
• Beta: 0.54